Razuprotafib - CAS 1008510-37-9

Razuprotafib (CAT: I008984) is indeed a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP). By targeting and inhibiting VE-PTP, razuprotafib prevents the dephosphorylation of the endothelial cell (EC)-specific receptor tyrosine kinase (RTK) Tie2. This inhibition leads to the restoration of Tie2 activation, which is crucial for maintaining endothelial function and vascular stability. Upregulation of VE-PTP is observed in stressed endothelium associated with various diseases. By restoring Tie2 activation, razuprotafib has the potential to improve endothelial function, stabilize blood vessels, and mitigate vascular leakage and inflammation. This makes razuprotafib a promising candidate for therapeutic interventions in conditions where endothelial dysfunction is implicated.

Catalog Number: I008984

CAS Number: 1008510-37-9

PubChem Substance ID:355200157

Molecular Formula: C26H26N4O6S3

Molecular Weight:586.696

Purity: ≥95%

* For research use only. Not for human or veterinary use.


SynonymsRazuprotafib;N-(4-{(2S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido}-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl}phenyl)sulfamic acid


Molecular Formula: C26H26N4O6S3
Molecular Weight586.696
Target:HPTPß inhibitor
SolubilitySoluble in DMSO
Storage0 - 4 °C for short term, or -20 °C for long term
Overview of Clinical ResearchOriginator: Procter &amp; Gamble<br /> Developer: Aerpio Pharmaceuticals; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; Medical Technology Enterprise Consortium; New York University; Quantum Leap Healthcare Collaborative<br /> Class: Amides; Antineoplastics; Carbamates; Eye disorder therapies; Small molecules; Sulfonic acids; Thiazoles; Thiophenes<br /> Mechanism of Action: Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists<br /> Orphan Drug Status: No<br /> New Molecular Entity: Yes<br /> Available For Licensing: Yes

Computed Descriptor

IUPAC Name[4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid